The approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in ...

Discover a study in which liver dysmorphy was observed in 95% of patients with a high ANALI score, and it was significantly ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...

GSK’s linerixibat has shown promising results in a late-stage trial of primary biliary cholangitis (PBC) patients with ...

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...

As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...

Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...

Topline results were announced from a phase 3 trial evaluating linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

RTY-694 increased protein levels and function of ABCB4 and BSEP in primary hepatocytes, two transporters that play a key role in bile composition ...

Ipsen has shared positive three-year results for Iqirvo (elafibranor) in patients with the rare cholestatic liver disease ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...

Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected ...